Paulson & Co’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Paulson & Co’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,000,000	Closed	-$8.92M	–	57
2017 Q4	$8.92M	Sell	4,000,000 -20,062,368	-83%	-$49.9M	0.17%	48
2017 Q3	$69.8M	Sell	24,062,368 -26,287	-0.1%	-$89.7K	1.25%	19
2017 Q2	$107M	Hold	24,088,655	–	–	1.45%	19
2017 Q1	$112M	Hold	24,088,655	–	–	1.49%	19
2016 Q4	$147M	Sell	24,088,655 -140,000	-0.6%	-$732K	1.85%	13
2016 Q3	$134M	Sell	24,228,655 -3,528,013	-13%	-$16.5M	1.45%	17
2016 Q2	$105M	Buy	27,756,668 +16,666,668	+150%	+$56.5M	1.07%	22
2016 Q1	$30.6M	Buy	11,090,000 +2,090,000	+23%	+$7.57M	0.23%	47
2015 Q4	$51M	Hold	9,000,000	–	–	0.31%	35
2015 Q3	$47.7M	Buy	9,000,000 +3,218,500	+56%	+$24.9M	0.25%	45
2015 Q2	$48M	Buy	5,781,500 +3,685,900	+176%	+$17.9M	0.22%	45
2015 Q1	$9.68M	Buy	+2,095,600	New	+$6.81M	0.05%	52

Other funds holding SGYP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Paulson & Co's SGYP Position: Q1 2018 in Review

Paulson & Co sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2018, closing a stake of 4,000,000 shares — an estimated $8.92M sold.

Paulson & Co first reported a position in SGYP in Q1 2015 and held it in 12 quarters. The position peaked at $147M in Q4 2016. 147 funds tracked by Wall St. Rank hold SGYP as of Q1 2018.

Paulson & Co reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2018 after selling out during the quarter.
Paulson & Co sold 4,000,000 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2018, an estimated $8.92M.
Paulson & Co first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2015 and held it in 12 quarters.
Paulson & Co's Synergy Pharmaceuticals, Inc Common Stock position peaked at $147M in Q4 2016.
147 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2018.

Based on Paulson & Co's 13F filing for Q1 2018, filed 15 May 2018.